# Envisioning Cannabinoid CB1 Receptor Biased Signaling as a Therapeutic Target for Schizophrenia. > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/envisioning-cannabinoid-cb1-receptor-biased-signaling-as-a-therapeutic-targ/ > **Published:** 2026-04-28T04:02:56-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T16:04:04-04:00 > **Clinical Summary:** The relationship between the endocannabinoid system and the emergence and treatment of schizophrenia-related symptoms continues to be a topic of significant ... --- CED Clinical Relevance  #62Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. 🔬 Evidence Watch  |  CED Clinic Journal The American journal of psychiatry Study Type [Clinical Study](https://cedclinic.com/cannabis-hyperemesis-syndrome-psychiatric-risk/) Population Human participants Why This Matters This item covers developments relevant to [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) and [clinical practice](https://cedclinic.com/cannabis-reproductive-health-women-clinical-evidence/). Clinicians monitoring evidence in this area should review the source material. Clinical Summary The relationship between the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) and the emergence and treatment of schizophrenia-related symptoms continues to be a topic of significant interest within psychiatry. Cannabis is the most widely used recreational drug worldwide, and individuals with schizophrenia use it at a much higher rate than the general population. The shared genetic risk for schizophrenia and [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) may partially account for this phenomenon. However, the exposure to cannabis in individuals at risk of schizophrenia appears to not only represent the manifestation of overlapping risks, but also pharmacological exacerbation of an already altered cortical system. Thus, [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) dose-dependently increases the likelihood of receiving a schizophrenia diagnosis, acutely exacerbates schizophrenia symptoms, and worsens long-term prognosis for individuals with schizophrenia. The psychoactive substance in cannabis, Δ Dr. Caplan’s Take “This is a development worth tracking. The clinical implications will become clearer as more evidence accumulates.” Clinical Perspective 🧠 Clinicians should review this item in the context of their current practice and patient population. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Envisioning%20Cannabinoid%20CB1%20Receptor%20Biased%20Signaling%20as%20a%20Therapeutic%20Target%20for%20Schizophrenia.%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2Fenvisioning-cannabinoid-cb1-receptor-biased-signaling-as-a-therapeutic-targ%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fenvisioning-cannabinoid-cb1-receptor-biased-signaling-as-a-therapeutic-targ%2F)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Envisioning%20Cannabinoid%20CB1%20Receptor%20Biased%20Signaling%20as%20a%20Therapeutic%20Target%20for%20Schizophrenia.%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2Fenvisioning-cannabinoid-cb1-receptor-biased-signaling-as-a-therapeutic-targ%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://pubmed.ncbi.nlm.nih.gov/41992094/](https://pubmed.ncbi.nlm.nih.gov/41992094/) Table of Contents - [FAQ](#FAQ)[Do people with schizophrenia use cannabis more than the general population?](#Do_people_with_schizophrenia_use_cannabis_more_than_the_general_population) - [Is the cannabis and schizophrenia link only about shared genetic risk?](#Is_the_cannabis_and_schizophrenia_link_only_about_shared_genetic_risk) - [How does cannabis use affect schizophrenia risk and its long-term course?](#How_does_cannabis_use_affect_schizophrenia_risk_and_its_long-term_course) - [Related](#Related) ## FAQ ### Do people with schizophrenia use cannabis more than the general population? Yes. The article notes that cannabis is the most widely used recreational drug worldwide and that individuals with schizophrenia use it at a much higher rate than the general population. The authors suggest that shared genetic risk for schizophrenia and cannabis use may partially account for this pattern. ### Is the cannabis and schizophrenia link only about shared genetic risk? Not according to the authors. They argue that cannabis exposure in people at risk of schizophrenia appears to represent not only overlapping risks but also pharmacological exacerbation of an already altered cortical system. In other words, cannabis may worsen brain systems that are already affected, beyond simply sharing risk factors with the illness. ### How does cannabis use affect schizophrenia risk and its long-term course? The authors state that cannabis use dose-dependently increases the likelihood of receiving a schizophrenia diagnosis, meaning more use is tied to a higher likelihood. They also state that it acutely worsens schizophrenia symptoms and worsens the long-term prognosis for people who already have schizophrenia. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).